Journal of Clinical Oncology, Vol 12, 1169-1176, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study

WS Velasquez, P McLaughlin, S Tucker, FB Hagemeister, F Swan, MA Rodriguez, J Romaguera, E Rubenstein and F Cabanillas
Section of Lymphoma, M.D. Anderson Cancer Center, Houston, TX.

PURPOSE: This study attempted to determine the efficacy of the combination of etoposide (VP-16), methyl-prednisolone, and cytarabine (Ara-C) with or without cisplatin in relapsing and refractory adult lymphoma patients. PATIENTS AND METHODS: The first 63 patients were randomized to receive VP-16 40 mg/m2/d for 4 days, methylprednisolone 500 mg intravenously daily for 5 days, and Ara-C 2 g/m2 intravenously over 2 to 3 hours on day 5 with or without cisplatin 25 mg/m2 IV administered by 24-hour infusion for 4 days (ESHA +/- P). Markedly different responses between ESHA (33%) and ESHAP (75%) led to deletion of the ESHA arm. A total of 122 patients on the ESHAP regimen were studied. RESULTS: Forty-five patients (37%) attained a complete remission (CR) and 33 (27%) attained a partial remission (PR), for a total response rate of 64%. The median duration of CR was 20 months, with 28% of remitters still in CR at 3 years. The overall median survival duration was 14 months; the survival rate at 3 years was 31%. Overall time to treatment failure (TTF) showed 10% of all patients to be alive and disease-free at 40 months. Response and survival rates were similar in patients with low-grade (n = 34), intermediate-grade (n = 67), transformed (n = 18), and high-grade (n = 3) lymphoma. The most significant factors for response and survival by multivariate analysis were the serum lactic dehydrogenase (LDH) level, tumor burden, and age (when analyzed as a continuous variable), while prior CR was highly significant by univariate analysis. A significant difference in survival was noted for patients with normal LDH levels and low- or intermediate-tumor burden or patients with low tumor burden and elevated LDH levels (55% 3-year survival rate) versus patients with elevated LDH levels and intermediate or high tumor burden (< 20%). Major toxicities included myelosuppression, with a median granulocyte count of 500/microL and platelet count of 70,000/microL. CONCLUSION: ESHAP was found to be an active, tolerable chemotherapy regimen for relapsing and refractory lymphoma. Applying a prognostic model based on tumor burden and serum LDH level shows significant differences in survival in this patient population.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. Numbenjapon, J. Wang, D. Colcher, T. Schluep, M. E. Davis, J. Duringer, L. Kretzner, Y. Yen, S. J. Forman, and A. Raubitschek Preclinical Results of Camptothecin-Polymer Conjugate (IT-101) in Multiple Human Lymphoma Xenograft Models Clin. Cancer Res., July 1, 2009; 15(13): 4365 - 4373. [Abstract] [Full Text] [PDF]

				H. NISHIMORI, N. FUJII, Y. MAEDA, K.-I. MATSUOKA, K. TAKENAKA, K. SHINAGAWA, K. IKEDA, K. MATSUO, M. HARADA, and M. TANIMOTO Efficacy and Feasibility of IDEA Therapy for Refractory or Relapsed Non-Hodgkin's Lymphoma Anticancer Res, May 1, 2009; 29(5): 1749 - 1754. [Abstract] [Full Text] [PDF]

				B.-S. Kim, D.-W. Kim, S.-A. Im, C. W. Kim, T.-Y. Kim, S.-S. Yoon, D. S. Heo, Y.-J. Bang, S. Park, B. K. Kim, et al. Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone Ann. Onc., January 1, 2009; 20(1): 121 - 128. [Abstract] [Full Text] [PDF]

				A. Martin, E. Conde, M. Arnan, M. A. Canales, G. Deben, J. M. Sancho, R. Andreu, A. Salar, P. Garcia-Sanchez, L. Vazquez, et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study Haematologica, December 1, 2008; 93(12): 1829 - 1836. [Abstract] [Full Text] [PDF]

				D. Maruyama, T. Watanabe, Y. Beppu, Y. Kobayashi, S.-W. Kim, K. Tanimoto, A. Makimoto, Y. Kagami, T. Terauchi, Y. Matsuno, et al. Primary Bone Lymphoma: A New and Detailed Characterization of 28 Patients in a Single-Institution Study Jpn. J. Clin. Oncol., March 1, 2007; 37(3): 216 - 223. [Abstract] [Full Text] [PDF]

				M. A. Moufarij, D. Sampath, M. J. Keating, and W. Plunkett Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal Blood, December 15, 2006; 108(13): 4187 - 4193. [Abstract] [Full Text] [PDF]

				T. J. Smith, J. Khatcheressian, G. H. Lyman, H. Ozer, J. O. Armitage, L. Balducci, C. L. Bennett, S. B. Cantor, J. Crawford, S. J. Cross, et al. 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline J. Clin. Oncol., July 1, 2006; 24(19): 3187 - 3205. [Abstract] [Full Text] [PDF]

				A. Olivieri, G. Santini, C. Patti, T. Chisesi, C. De Souza, A. Rubagotti, S. Aversa, A. Billio, A. Porcellini, M. Candela, et al. Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG Ann. Onc., December 1, 2005; 16(12): 1941 - 1948. [Abstract] [Full Text] [PDF]

				E. T. Wong Management of Central Nervous System Lymphomas Using Monoclonal Antibodies: Challenges and Opportunities Clin. Cancer Res., October 1, 2005; 11(19): 7151s - 7157s. [Abstract] [Full Text] [PDF]

				J. Rodriguez, M. D. Caballero, A. Gutierrez, C. Solano, R. Arranz, J. J. Lahuerta, J. Sierra, M. Gandarillas, J. A. Perez-Simon, J. Zuazu, et al. Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin's lymphoma not achieving complete response after induction chemotherapy: the GEL/TAMO experience Ann. Onc., October 1, 2004; 15(10): 1504 - 1509. [Abstract] [Full Text] [PDF]

				T. Kewalramani, A. D. Zelenetz, S. D. Nimer, C. Portlock, D. Straus, A. Noy, O. O'Connor, D. A. Filippa, J. Teruya-Feldstein, A. Gencarelli, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma Blood, May 15, 2004; 103(10): 3684 - 3688. [Abstract] [Full Text] [PDF]

				M. Jermann, L. M. Jost, Ch. Taverna, E. Jacky, H. P. Honegger, D. C. Betticher, F. Egli, Th. Kroner, and R. A. Stahel Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study Ann. Onc., March 1, 2004; 15(3): 511 - 516. [Abstract] [Full Text] [PDF]

				K. Belhadj, F. Reyes, J.-P. Farcet, H. Tilly, C. Bastard, R. Angonin, E. Deconinck, F. Charlotte, V. Leblond, E. Labouyrie, et al. Hepatosplenic {gamma}{delta} T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients Blood, December 15, 2003; 102(13): 4261 - 4269. [Abstract] [Full Text] [PDF]

				P. A. Hamlin, A. D. Zelenetz, T. Kewalramani, J. Qin, J. M. Satagopan, D. Verbel, A. Noy, C. S. Portlock, D. J. Straus, J. Yahalom, et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma Blood, September 15, 2003; 102(6): 1989 - 1996. [Abstract] [Full Text] [PDF]

				J.M. Vose, M. Crump, H. Lazarus, C. Emmanouilides, D. Schenkein, J. Moore, S. Frankel, I. Flinn, W. Lovelace, J. Hackett, et al. Randomized, Multicenter, Open-Label Study of Pegfilgrastim Compared With Daily Filgrastim After Chemotherapy for Lymphoma J. Clin. Oncol., February 1, 2003; 21(3): 514 - 519. [Abstract] [Full Text] [PDF]

				M. D. Caballero, J. A. Perez-Simon, A. Iriondo, J. J. Lahuerta, J. Sierra, J. Marin, M. Gandarillas, R. Arranz, J. Zuazu, V. Rubio, et al. High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group Ann. Onc., January 1, 2003; 14(1): 140 - 151. [Abstract] [Full Text] [PDF]

				A. M. Tsimberidou, P. McLaughlin, A. Younes, M. A. Rodriguez, F. B. Hagemeister, A. Sarris, J. Romaguera, M. Hess, T. L. Smith, Y. Yang, et al. Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma Blood, December 15, 2002; 100(13): 4351 - 4357. [Abstract] [Full Text] [PDF]

				T. Saito, Y. Matsuno, R. Tanosaki, T. Watanabe, Y. Kobayashi, and K. Tobinai {gamma}{delta} T-cell neoplasms: a clinicopathological study of 11 cases Ann. Onc., November 1, 2002; 13(11): 1792 - 1798. [Abstract] [Full Text] [PDF]

				N. L. Kobrinsky, R. Sposto, N. R. Shah, J. R. Anderson, C. DeLaat, M. Morse, P. Warkentin, G. S. Gilchrist, M. D. Cohen, D. Shina, et al. Outcomes of Treatment of Children and Adolescents With Recurrent Non-Hodgkin's Lymphoma and Hodgkin's Disease With Dexamethasone, Etoposide, Cisplatin, Cytarabine, and L-Asparaginase, Maintenance Chemotherapy, and Transplantation: Children's Cancer Group Study CCG-5912 J. Clin. Oncol., May 1, 2001; 19(9): 2390 - 2396. [Abstract] [Full Text] [PDF]

				M. Duvic, K. Hymes, P. Heald, D. Breneman, A. G. Martin, P. Myskowski, C. Crowley, and R. C. Yocum Bexarotene Is Effective and Safe for Treatment of Refractory Advanced-Stage Cutaneous T-Cell Lymphoma: Multinational Phase II-III Trial Results J. Clin. Oncol., May 1, 2001; 19(9): 2456 - 2471. [Abstract] [Full Text] [PDF]

				T. Kewalramani, A. D. Zelenetz, E. E. Hedrick, G. B. Donnelly, S. Hunte, A. C. Priovolos, J. Qin, N. C. Lyons, J. Yahalom, S. D. Nimer, et al. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis Blood, October 1, 2000; 96(7): 2399 - 2404. [Abstract] [Full Text] [PDF]

				C. H. Moskowitz, J. R. Bertino, J. R. Glassman, E. E. Hedrick, S. Hunte, N. Coady-Lyons, D. B. Agus, A. Goy, J. Jurcic, A. Noy, et al. Ifosfamide, Carboplatin, and Etoposide: A Highly Effective Cytoreduction and Peripheral-Blood Progenitor-Cell Mobilization Regimen for Transplant-Eligible Patients With Non-Hodgkin's Lymphoma J. Clin. Oncol., December 1, 1999; 17(12): 3776 - 3785. [Abstract] [Full Text] [PDF]

				T. A. Davis, C. A. White, A. J. Grillo-Lopez, W. S. Velasquez, B. Link, D. G. Maloney, R. O. Dillman, M. E. Williams, A. Mohrbacher, R. Weaver, et al. Single-Agent Monoclonal Antibody Efficacy in Bulky Non-Hodgkin's Lymphoma: Results of a Phase II Trial of Rituximab J. Clin. Oncol., June 1, 1999; 17(6): 1851 - 1851. [Abstract] [Full Text] [PDF]

				J.-Y. Blay, F. Gomez, C. Sebban, T. Bachelot, P. Biron, C. Guglielmi, A. Hagenbeek, R. Somers, F. Chauvin, and T. Philip The International Prognostic Index Correlates to Survival in Patients With Aggressive Lymphoma in Relapse: Analysis of the PARMA Trial Blood, November 15, 1998; 92(10): 3562 - 3568. [Abstract] [Full Text] [PDF]

				L. H. Sehn, J. H. Antin, L. N. Shulman, P. Mauch, A. Elias, M. E. Kadin, and C. Wheeler Primary Diffuse Large B-Cell Lymphoma of the Mediastinum: Outcome Following High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation Blood, January 15, 1998; 91(2): 717 - 723. [Abstract] [Full Text] [PDF]

				J.-P. Droz, S. Culine, P. Biron, and A. Kramar High-Dose Chemotherapy in Adult Solid Tumors and Lymphoproliferative Disorders: The Need for Randomized Trials Oncologist, April 1, 1997; 2(2): 83 - 93. [Abstract] [Full Text] [PDF]

				T. Philip, C. Guglielmi, A. Hagenbeek, R. Somers, H. Van Der Lelie, D. Bron, P. Sonneveld, C. Gisselbrecht, J.-Y. Cahn, J.-L. Harousseau, et al. Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma N. Engl. J. Med., December 7, 1995; 333(23): 1540 - 1545. [Abstract] [Full Text] [PDF]

				J. M. Vose Treatment for Non-Hodgkin's Lymphoma in Relapse -- What Are the Alternatives? N. Engl. J. Med., December 7, 1995; 333(23): 1565 - 1566. [Full Text]